Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
CYCCP's Cash-to-Debt is ranked higher than
94% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CYCCP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CYCCP' s Cash-to-Debt Range Over the Past 10 Years
Min: 1  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.73
CYCCP's Equity-to-Asset is ranked higher than
60% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYCCP: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
CYCCP' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.51  Med: 0.73 Max: 0.85
Current: 0.73
-3.51
0.85
Interest Coverage No Debt
CYCCP's Interest Coverage is ranked higher than
91% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCCP: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYCCP' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -23.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1678.53
CYCCP's Operating Margin % is ranked lower than
81% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CYCCP: -1678.53 )
Ranked among companies with meaningful Operating Margin % only.
CYCCP' s Operating Margin % Range Over the Past 10 Years
Min: -25222.48  Med: -2176.86 Max: -831.79
Current: -1678.53
-25222.48
-831.79
Net Margin % -1398.70
CYCCP's Net Margin % is ranked lower than
80% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CYCCP: -1398.70 )
Ranked among companies with meaningful Net Margin % only.
CYCCP' s Net Margin % Range Over the Past 10 Years
Min: -19110.14  Med: -2164.44 Max: -737.76
Current: -1398.7
-19110.14
-737.76
ROE % -75.79
CYCCP's ROE % is ranked lower than
72% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CYCCP: -75.79 )
Ranked among companies with meaningful ROE % only.
CYCCP' s ROE % Range Over the Past 10 Years
Min: -154.79  Med: -86.54 Max: -42.99
Current: -75.79
-154.79
-42.99
ROA % -54.88
CYCCP's ROA % is ranked lower than
69% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CYCCP: -54.88 )
Ranked among companies with meaningful ROA % only.
CYCCP' s ROA % Range Over the Past 10 Years
Min: -86.17  Med: -55.62 Max: -34.56
Current: -54.88
-86.17
-34.56
ROC (Joel Greenblatt) % -12282.99
CYCCP's ROC (Joel Greenblatt) % is ranked lower than
87% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CYCCP: -12282.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYCCP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12282.99  Med: -5513.32 Max: -1007.24
Current: -12282.99
-12282.99
-1007.24
3-Year Revenue Growth Rate -34.10
CYCCP's 3-Year Revenue Growth Rate is ranked higher than
93% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CYCCP: -34.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYCCP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.25 Max: 92.8
Current: -34.1
0
92.8
3-Year EBITDA Growth Rate -24.10
CYCCP's 3-Year EBITDA Growth Rate is ranked lower than
86% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CYCCP: -24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CYCCP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.2  Med: -32.15 Max: 13.8
Current: -24.1
-50.2
13.8
3-Year EPS without NRI Growth Rate -39.10
CYCCP's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CYCCP: -39.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CYCCP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.2  Med: -34 Max: 22.9
Current: -39.1
-52.2
22.9
GuruFocus has detected 3 Warning Signs with Cyclacel Pharmaceuticals Inc $CYCCP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYCCP's 10-Y Financials

Financials (Next Earnings Date: 2017-06-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CYCCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP6.254.806% Convertible Exchangeable Preferred Stock

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:VITIF, OTCPK:BRPHF, OTCPK:HSTC, OTCPK:GLAG, OTCPK:NTRR, OTCPK:NSPX, OTCPK:MYMSF, OTCPK:TLOG, OTCPK:ERGO, OTCPK:ENTB, OTCPK:CGYG, OTCPK:HDVY, OTCPK:LCAR, OTCPK:BPSR, OTCPK:KNBIF, OTCPK:CAPS, OTCPK:FPMI, OTCPK:ICOTF, OTCPK:CRXM, OTCPK:ARNI » details
Traded in other countries:UXI3.Germany,
Headquarter Location:USA
Cyclacel Pharmaceuticals Inc is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in US and UK.

Cyclacel Pharmaceuticals Inc was founded in August 13, 1996 and is incorporated in Delaware. The Company is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Its clinical development priorities are focused on sapacitabine only, its second drug candidate, seliciclib, is a novel, orally-available, CDK clinical development priorities are focused on sapacitabine as an orphan drug for the treatment of both Acute Myeloid Leukemia, or AML, and Myelodysplastic Syndromes, or MDS. The Company is currently evaluating sapacitabine in a Phase 3 study being conducted under a Special Protocol Assessment, or SPA, with the FDA for the front-line treatment of AML in the elderly. The Company is also exploring sapacitabine in Phase 2 studies for MDS, non-small cell lung cancer, or NSCLC, and chronic lymphocytic leukemia, or CLL and in a Phase 1 study in solid tumors in combination with seliciclib, another of its drug candidates. Sapacitabine has been evaluated in approximately 1,000 patients to date. In addition, in polo-like kinase, or PLK inhibitor program, the Company has discovered CYC140 and other small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. The Company retains all marketing rights for these compounds internationally.

Top Ranked Articles about Cyclacel Pharmaceuticals Inc

Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results

BERKELEY HEIGHTS, N.J., March 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2016 financial results on Tuesday, March 28, 2017. The Company will host a conference call and live webcast at 4:30 p.m. EDT on the same day. 
Conference call information:  US/Canada call: (877) 493-9121 / international call: (973) 582-2750 
US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406 
Code for live and archived conference call is 91915665
For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.  About Cyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. The Cyclacel is analyzing stratified and exploratory subgroups from a Phase 3 study of sapacitabine in elderly patients with AML. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com. Forward-looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. © Copyright 2017 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.  
Contacts

Company: Paul McBarron, (908) 517-7330, [email protected]
Investor Relations: Russo Partners LLC, Alexander Fudukidis, (646) 942-5632, [email protected]

Read more...
Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

CYC065 found effective against lung cancer cell lines including those with KRAS mutations
BERKELEY HEIGHTS, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), today announced the publication of a peer-reviewed journal article featuring the company’s cyclin dependent kinase 2/9 (CDK2/9) inhibitors. In an article published in the Journal of National Cancer Institute (JNCI), preclinical data demonstrated that both Cyclacel’s CYC065, a second-generation, clinical stage, CDK2/9 inhibitor, and CCT68127, a pre-clinical stage CDK2/9 inhibitor, demonstrated prominent antitumor activity against lung cancer through anaphase catastrophe, a novel, cancer specific mechanism of action.The Journal of National Cancer Institute article entitled, "Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer," demonstrates that CYC065 and CCT68127 cause multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes, known as anaphase catastrophe. This novel mechanism of action offers an innovative approach to combat aneuploid cancer cells which contain abnormal numbers of chromosomes. Aneuploidy is a hallmark for cancer development and occurs in virtually every cancer, but is particularly found in lung cancer. Approximately 90 percent of cancer cells in solid tumors and blood cancer are aneuploid.The article further reported that inhibition of CDK2 was the key mechanism of action and, as a consequence, lung cancer cells underwent apoptosis or cell suicide by induction of a novel mechanism called anaphase catastrophe. Similarly to a previous report on seliciclib (Cyclacel’s first generation CDK inhibitor), lung cancer cells with mutant KRAS were particularly sensitive to CYC065 and CCT68127. Combination of CCT68127 with the MEK inhibitor, trametinib, was synergistic. An efficacy study in syngeneic cancer models of lung cancer with mutant KRAS demonstrated tumor growth inhibitory effect and a significant decrease of circulating tumor cells.Citation:
Kawakami M, Lisa, Mustachio M, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, J. Lee J, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst (2017) 109(6): djw297.About CYC065Cyclacel’s second generation CDK2/9 inhibitor, CYC065, is being evaluated in an ongoing, first-in-human, Phase 1 trial in patients with advanced solid tumors. In addition to determining safety and recommended dosing for Phase 2, the study aims to investigate CYC065’s effects on the Mcl-1 biomarker, which is implicated in the evolution of resistance in cancer. Evidence of target engagement with prolonged Mcl-1 suppression in peripheral blood cells was observed in patient samples from the study, as well as decreases in kinase substrate phosphorylation and increases in PARP cleavage, which were consistent with the Company’s preclinical data. CYC065 is mechanistically similar but has much higher dose potency, in vitro and in vivo, and improved metabolic stability than seliciclib, Cyclacel's first generation CDK inhibitor.  Similar to palbociclib, the first CDK inhibitor approved by FDA in 2015, CYC065 may be most useful as a therapy for patients with both liquid and solid tumors in combination with other anticancer agents, including Bcl-2 antagonists, such as venetoclax, or HER2 inhibitors, such as trastuzumab.About Cyclacel Pharmaceuticals, Inc.Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel's DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. The transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. Cyclacel is analyzing stratified and exploratory subgroups from a Phase 3 study of sapacitabine in elderly patients with AML. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com.Forward-looking StatementsThis news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.© Copyright 2017 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. 
Contacts

Company:
Paul McBarron, (908) 517-7330, [email protected]

Investor Relations:
Russo Partners LLC, Alexander Fudukidis, (646) 942-5632, [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.30
CYCCP's PB Ratio is ranked higher than
94% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CYCCP: 1.30 )
Ranked among companies with meaningful PB Ratio only.
CYCCP' s PB Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.84 Max: 16.6
Current: 1.3
0.22
16.6
PS Ratio 16.65
CYCCP's PS Ratio is ranked higher than
54% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CYCCP: 16.65 )
Ranked among companies with meaningful PS Ratio only.
CYCCP' s PS Ratio Range Over the Past 10 Years
Min: 5.02  Med: 49.39 Max: 836.97
Current: 16.65
5.02
836.97
Current Ratio 3.73
CYCCP's Current Ratio is ranked higher than
50% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CYCCP: 3.73 )
Ranked among companies with meaningful Current Ratio only.
CYCCP' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 3.93 Max: 7.34
Current: 3.73
0.96
7.34
Quick Ratio 3.73
CYCCP's Quick Ratio is ranked higher than
52% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CYCCP: 3.73 )
Ranked among companies with meaningful Quick Ratio only.
CYCCP' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 3.91 Max: 7.34
Current: 3.73
0.96
7.34
Days Sales Outstanding 890.63
CYCCP's Days Sales Outstanding is ranked lower than
99% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CYCCP: 890.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYCCP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 568.15  Med: 777.81 Max: 6980.27
Current: 890.63
568.15
6980.27

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.80
CYCCP's Dividend Yield % is ranked lower than
99.99% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. CYCCP: 4.80 )
Ranked among companies with meaningful Dividend Yield % only.
CYCCP' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 161.75
Current: 4.8
0
161.75
Forward Dividend Yield % 9.60
CYCCP's Forward Dividend Yield % is ranked lower than
99.99% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. CYCCP: 9.60 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.80
CYCCP's 5-Year Yield-on-Cost % is ranked lower than
99.99% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. CYCCP: 4.80 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CYCCP' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 161.75
Current: 4.8
0
161.75
3-Year Average Share Buyback Ratio -38.30
CYCCP's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CYCCP: -38.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYCCP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.5  Med: -41.2 Max: 0
Current: -38.3
-144.5
0

Valuation & Return

vs
industry
vs
history

More Statistics

Beta0.75
Short Percentage of Float0.04%
52-Week Range $4.21 - 55.20
» More Articles for CYCCP

Headlines

Articles On GuruFocus.com
Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations f Apr 04 2017 
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Apr 02 2017 
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results Mar 21 2017 
Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism Mar 07 2017 
Wilbur Ross Buys Two New Stakes in First Quarter Jun 15 2015 
Insider Cluster Buying Reported in Several Companies May 30 2013 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)